DYN - NASDAQ
Dyne Therapeutics, Inc.
$17.99
-3.4%Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
At a Glance
Live Snapshotdyn
Total Liabilities and Equity
Last Annual Value
1.19B
3-Year CAGR
57%
5-Year CAGR
27%
10-Year CAGR
-20%
Dyne Therapeutics, Inc. Competitors Analysis of Total Liabilities and Equity
| Company | Total Liabilities and Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Dyne Therapeutics, Inc. NASDAQ:DYN | 1.19B | 93.0% | 22.8% | -21.3% | |
 CG Oncology, Inc. Common stock NASDAQ:CGON | 791.59M | 58.4% | 68.3% | N/A | |
 Celcuity Inc. NASDAQ:CELC | 466.56M | 34.6% | 40.3% | 54.4% | |
 Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 842.81M | 9.2% | 23.4% | N/A | |
 Apogee Therapeutics, Inc. NASDAQ:APGE | 937.13M | 32.7% | N/A | N/A | |
 Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | 1.53B | 0.9% | 0.1% | 11.0% | |
 Soleno Therapeutics, Inc. NASDAQ:SLNO | 563.83M | 46.1% | 73.8% | 58.7% |
Dyne Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your DYN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.